Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

Bibliographic Details
Main Authors:	Amin, Janaki, Boyd, Mark A., Kumarasamy, Nagalingeswaran, Moore, Cecilia L., Losso, Marcello H., Nwizu, Chidi A., Mohapi, Lerato, Kerr, Stephen J., Sohn, Annette H., Teppler, Hedy, Renjifo, Boris, Molina, Jean-Michel, Emery, Sean, Cooper, David A.
Format:	Online
Language:	English
Published:	Public Library of Science 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344344/

Similar Items

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
by: Amin, Janaki, et al.
Published: (2015)

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
by: Martin, Allison, et al.
Published: (2013)

Lopinavir/ritonavir monotherapy in clinical practice
by: Caso, A, et al.
Published: (2010)

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy
by: Martin, Allison, et al.
Published: (2013)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
by: Ceccaldi, Pierre-François, et al.
Published: (2010)

The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa
by: Schneider, Karen, et al.
Published: (2013)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
by: Baran, RW, et al.
Published: (2010)

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial
by: Lockman, Shahin, et al.
Published: (2012)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
by: Martinez, Beatriz Larru, et al.
Published: (2010)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
by: Reyskens, Kathleen M. S. E., et al.
Published: (2013)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
by: Reyskens, Kathleen M. S. E., et al.
Published: (2013)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Published: (2015)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
by: Tookey, Pat, et al.
Published: (2014)

USE OF LOPINAVIR/RITONAVIR ASSOCIATED WITH ERGOTAMINE RESULTING IN FOOT AMPUTATION: BRIEF COMMUNICATION
by: Ferry, Fernando Raphael de Almeida, et al.
Published: (2014)

Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230
by: Vardhanabhuti, Saran, et al.
Published: (2016)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
by: Broder, MS, et al.
Published: (2010)

A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial
by: Ulbricht, K.U, et al.
Published: (2011)

Long-Term Safety from the Raltegravir Clinical Development Program
by: Teppler, Hedy, et al.
Published: (2011)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
by: Nozza, S, et al.
Published: (2010)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
by: Pereira, A, et al.
Published: (2010)

Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
by: Surah, S, et al.
Published: (2010)

Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
by: Murphy, Richard A., et al.
Published: (2012)

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag–protease genes
by: Sutherland, Katherine A., et al.
Published: (2014)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
by: Sutherland, K. A., et al.
Published: (2015)

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
by: Skinner-Adams, Tina S., et al.
Published: (2012)

Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study
by: Santos, José R., et al.
Published: (2013)

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults
by: Byakika-Kibwika, Pauline, et al.
Published: (2011)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
by: Zhang, C, et al.
Published: (2010)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
by: Maroldo, L, et al.
Published: (2010)

The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy
by: Decloedt, Eric H., et al.
Published: (2012)

Treatment of HIV-2 infection with ritonavir/lopinavir: results at 60 months. A single-center study of 9 patients
by: Genet, Philippe, et al.
Published: (2010)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
by: Byakika-Kibwika, Pauline, et al.
Published: (2012)

Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam
by: Lan, Nguyen Thi Ngoc, et al.
Published: (2014)

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
by: Clumeck, Nathan, et al.
Published: (2014)

Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes
by: Grossman, Zehava, et al.
Published: (2014)

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
by: Shiau, Stephanie, et al.
Published: (2014)

Lopinavir/Ritonavir Impairs Physical Strength in Association with Reduced Igf1 Expression in Skeletal Muscle of Older Mice
by: Wong, Siu, et al.
Published: (2013)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
by: Rattanapunya, Siwalee, et al.
Published: (2015)

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
by: Kredo, T., et al.
Published: (2016)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
by: Gianotti, Nicola, et al.
Published: (2014)